NASDAQ:AERIAerie Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerie Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.06 +0.34 (+2.31 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$14.77Now: $15.06▼$15.7850-Day Range$13.67MA: $14.93▼$16.1352-Week Range$10.80Now: $15.06▼$36.93Volume823,938 shsAverage Volume934,027 shsMarket Capitalization$699.84 millionP/E RatioN/ADividend YieldN/ABeta0.9 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingAerie Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.43, Aerie Pharmaceuticals has a potential upside of 135.2% from its current price of $15.06.Amount of Analyst CoverageAerie Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesAerie Pharmaceuticals has received 760 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAerie Pharmaceuticals has received 524 “underperform” votes. (Add your “underperform” vote.)Community SentimentAerie Pharmaceuticals has received 59.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote “Outperform” if you believe AERI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAerie Pharmaceuticals does not currently pay a dividend.Dividend GrowthAerie Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerie Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,350.00 in company stock.Percentage Held by InsidersOnly 8.71% of the stock of Aerie Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($3.44) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerie Pharmaceuticals is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerie Pharmaceuticals is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerie Pharmaceuticals has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AERI Previous Symbol CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone919-237-5300Debt Debt-to-Equity Ratio1.61 Current Ratio4.28 Quick Ratio4.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$69.89 million Price / Sales10.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book4.18Profitability EPS (Most Recent Fiscal Year)($3.40) Net Income$-199,580,000.00 Net Margins-252.92% Return on Equity-95.74% Return on Assets-39.98%Miscellaneous Employees353 Outstanding Shares46,470,000Market Cap$699.84 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:AERI Rates by TradingView Receive AERI News and Ratings via Email Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter. Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions How has Aerie Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AERI stock has increased by 3.5% and is now trading at $15.06. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aerie Pharmaceuticals. When is Aerie Pharmaceuticals' next earnings date? Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aerie Pharmaceuticals. How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced its earnings results on Wednesday, May, 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.08. The business had revenue of $20.34 million for the quarter, compared to analysts' expectations of $21.04 million. Aerie Pharmaceuticals had a negative return on equity of 95.74% and a negative net margin of 252.92%. View Aerie Pharmaceuticals' earnings history. What price target have analysts set for AERI? 14 brokers have issued 1-year price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $17.00 to $56.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $35.43 in the next year. This suggests a possible upside of 135.2% from the stock's current price. View analysts' price targets for Aerie Pharmaceuticals. What are Wall Street analysts saying about Aerie Pharmaceuticals stock? Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock: 1. According to Zacks Investment Research, "Aerie reported mixed results for the fourth quarter of 2019, as the loss came in wider than expected, while sales surpassed expectations. The volumes picked up in the last two months of 2019. Aerie has an impressive portfolio of two ophthalmology drugs — Rhopressa and Rocklatan. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension, while Rocklatan is a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Xalatan. Aerie also obtained the approval of Rhokiinsa in Europe. Approval in additional geographies will boost sales. Glaucoma is one of the largest segments in the ophthalmic market. While the targeted market represents potential, Aerie faces stiff competition from Lumigan and Vyzulta, among others. Shares have underperformed the industry in the past year." (2/24/2020) 2. HC Wainwright analysts commented, "We recently lowered our 2019 revenue to just under $80M vs. prior guidance of $110-120M, and Aeri just lowered to $70-80M. While this looks far below consensus of $98M, we believe current expectation were more in the $85M range, thus guidance is not too far below that. Importantly, we believe the guidance is very achievable, and based only on what the company is already seeing internally in terms of orders, leading indicators and managed care progress, rather than on aggressive market-research based assumptions." (8/8/2019) Has Aerie Pharmaceuticals been receiving favorable news coverage? Media headlines about AERI stock have trended neutral on Saturday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutAerie Pharmaceuticals. Are investors shorting Aerie Pharmaceuticals? Aerie Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 9,720,000 shares, an increase of 5.1% from the April 15th total of 9,250,000 shares. Based on an average daily trading volume, of 962,900 shares, the days-to-cover ratio is presently 10.1 days. Currently, 24.2% of the shares of the stock are short sold. View Aerie Pharmaceuticals' Current Options Chain. Who are some of Aerie Pharmaceuticals' key competitors? Some companies that are related to Aerie Pharmaceuticals include Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Beam Therapeutics (BEAM), I-Mab (BDTX), Regenxbio (RGNX) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Micron Technology (MU), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Incyte (INCY), Puma Biotechnology (PBYI) and Alibaba Group (BABA). Who are Aerie Pharmaceuticals' key executives? Aerie Pharmaceuticals' management team includes the following people: Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)Mr. Thomas A. Mitro, Pres & COO (Age 61)Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)Ms. Jessica Crespo CPA, Director of Accounting What is Aerie Pharmaceuticals' stock symbol? Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI." Who are Aerie Pharmaceuticals' major shareholders? Aerie Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (14.50%), BlackRock Inc. (7.50%), Levin Capital Strategies L.P. (3.23%), Fred Alger Management LLC (3.01%), Bank of New York Mellon Corp (2.91%) and Rice Hall James & Associates LLC (2.77%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View institutional ownership trends for Aerie Pharmaceuticals. Which major investors are selling Aerie Pharmaceuticals stock? AERI stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Foresite Capital Management II LLC, Foresite Capital Management IV LLC, Invesco Ltd., Levin Capital Strategies L.P., Granahan Investment Management Inc. MA, Frontier Capital Management Co. LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Aerie Pharmaceuticals. Which major investors are buying Aerie Pharmaceuticals stock? AERI stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co., Wellington Management Group LLP, Fred Alger Management LLC, SG Americas Securities LLC, Citigroup Inc., Nuveen Asset Management LLC, Tarsadia Capital LLC, and Balyasny Asset Management LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr. View insider buying and selling activity for Aerie Pharmaceuticals. How do I buy shares of Aerie Pharmaceuticals? Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aerie Pharmaceuticals' stock price today? One share of AERI stock can currently be purchased for approximately $15.06. How big of a company is Aerie Pharmaceuticals? Aerie Pharmaceuticals has a market capitalization of $699.84 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe. What is Aerie Pharmaceuticals' official website? The official website for Aerie Pharmaceuticals is www.aeriepharma.com. How can I contact Aerie Pharmaceuticals? Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
